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Summary
 
It has been believed that the Fas expressed on human peripheral blood T cells (PBT) is non-
functional, because these cells are insensitive to agonistic anti-Fas/Apo-1 mAbs that efficiently
kill in vitro–activated T cells and many Fas-expressing cell lines. Here, we demonstrate that
membrane-bound Fas ligand (FasL) kills both fresh and in vitro–activated PBT, indicating that
the Fas expressed on fresh PBT is functional. In contrast, soluble FasL kills only the latter. Na-
ive T cells in umbilical cord blood do not express Fas, but can be induced to express Fas by
IFN-
 
g
 
 or by a combination of IL-2 and anti-CD28 mAb, after which they acquire sensitivity
to membrane but not to soluble FasL. Soluble FasL inhibited the killing of fresh PBT by mem-
brane FasL. These results indicate that the shedding of FasL from the membrane is a mechanism
for downregulating at least part of its killing activity.
 
F
 
as (also called Apo-1 or CD95) and Fas ligand (FasL)
play crucial roles in homeostasis and self-tolerance of
 
lymphocytes in both humans and mice (1). FasL also works
as a cytotoxic effector molecule of CTL and NK cells. FasL
is constitutively expressed in the testis and eyes, and it has
been implicated in the property of immune privilege in these
organs (2, 3). At the same time, the Fas-FasL system is a
double-edged sword (4) in that both the diminution and
enhancement of this system have pathogenic effects. Loss-
of-function mutations of Fas and FasL result in lymphopro-
liferative and autoimmune diseases. FasL expressed on acti-
vated T cells seems partly responsible for the tissue damage
in fulminant hepatitis (5) and graft-versus-host disease (6,
7). It has been reported that the thyrocytes in patients with
Hashimoto disease express both Fas and FasL, and commit
suicide similar to the activation-induced cell death of T cells
(8). It has been suggested that the Fas-FasL system plays a
role in the loss of CD4
 
1
 
 T cells in AIDS patients (9, 10).
Therefore, strategies for up- or downregulating the Fas-
FasL system might have therapeutic value for these diseases.
However, since Fas is expressed rather ubiquitously in a
wide range of normal tissues, the side effects of such treat-
ments on normal cells should be carefully evaluated.
FasL is a 40-kD type II transmembrane protein that is
homologous to TNF. FasL induces apoptosis by binding to
its membrane receptor, Fas (11). TNF-
 
a
 
, which is also syn-
thesized as a type II transmembrane protein, is cleaved into a
17-kD soluble form by proteolysis, and its soluble form causes
cachexia. Recently, the novel disintegrin metalloprotease
(TNF alpha-converting enzyme, TACE) that mediates this
process was identified (12, 13). Similarly, the TNF-homol-
ogous portion of membrane FasL is cleaved into a 26-kD
soluble form by a metalloprotease (14, 15), although it is
unknown whether the FasL cleavage is also performed by
TACE. This soluble human FasL efficiently induces apo-
ptosis in some Fas-expressing cells. In contrast, mouse solu-
ble FasL loses its killing activity (16).
The function of Fas expressed on various cells has been
investigated using agonistic anti-Fas/Apo-1 mAbs, and the
results have indicated that the expression of Fas does not
necessarily mean that cells are susceptible to these mAbs (17,
18). A large fraction of the peripheral blood T cells (PBT)
freshly isolated from adult humans express Fas. These Fas
 
1
 
PBT correspond to CD45RO
 
1
 
 PBT cells, which have been
postulated to be memory T cells. In spite of having readily
detectable levels of Fas expression, these cells are totally re-
sistant to agonistic anti-Fas mAbs (19–21). Virtually all mu-
rine T cells from peripheral lymphoid organs constitutively
express Fas, but they are also resistant to anti-Fas mAb
treatments (22). Therefore, it has been concluded that the
Fas expressed on peripheral mature T cells is nonfunctional.
However, we recently discovered that a recombinant soluble
mouse FasL that carries nearly the complete extracellular
region of FasL (termed WX1) efficiently kills mature T
cells in freshly isolated mouse splenocytes or lymph node
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cells (16). It should be noticed that, unlike naturally pro-
cessed mouse soluble FasL, WX1 is biologically active. In
this study, we examined the susceptibility of human PBT to
the membrane and soluble forms of human FasL and found
that they exhibited differential cytotoxic activity.
 
Materials and Methods
 
Preparation of Adult Peripheral and Umbilical Cord Blood Lympho-
cytes.
 
Heparinized adult peripheral and cord blood were ob-
tained from healthy adult volunteers and newborn babies deliv-
ered by Cesarean section, respectively, after obtaining informed
consent. Samples were diluted with an equal volume of PBS and
the lymphoid fraction was separated by gradient centrifugation us-
ing Ficoll-Paque Plus (Pharmacia, Uppsala, Sweden). ConA blasts
were prepared from adult PBL by cultivation with 5 
 
m
 
g/ml of
ConA (Sigma Chemical Co., St. Louis, MO) and 10 ng/ml of re-
combinant human IL-2 (Ajinomoto Pharmaceutical Co., Tokyo,
Japan) for 48 h, followed by incubation in the presence of IL-2
alone for 5 d. Dead cells were removed by gradient centrifugation
using Histopaque 1083 (Sigma). Cells were washed twice and sus-
pended in RPMI 1640 medium (Nikken BioMedical Laboratory,
Kyoto, Japan) supplemented with 10% FCS, 100 U/ml benzyl-
penicillin potassium (Meiji Seika Co., Tokyo, Japan), and 100
 
m
 
g/ml streptomycin sulfate (Meiji Seika). To induce Fas expres-
sion in cord blood lymphocytes, cells were cultured for 20 h with
recombinant human IFN-
 
g
 
 (10 ng/ml; PeproTech Inc., Rocky
Hill, NJ), IL-2 (10 ng/ml), or in a plate coated with anti-CD28 mAb
(PharMingen, San Diego, CA) at 10 
 
m
 
g/ml in 10 mM Tris-HCl,
pH 8.0, at 37
 
8
 
C for 1 h. Further analyses of the expression and
function of Fas in these cells were performed as described below.
 
Induction of Apoptosis by Transformants Expressing FasL, Soluble FasL,
and Anti-Fas Monoclonal Antibody.
 
Transformant 1A12, express-
ing human FasL lacking a cytoplasmic region (amino acids 8-69),
was established as previously described (23). Soluble human FasL
was purified from the culture medium of the 1A12 cells using an
affinity column coupled with anti-human FasL mAb (4H9) (24), and
the purified protein was designated as AL-1. Recombinant solu-
ble mouse FasL (WX1) consisting of the signal sequence derived
from G-CSF and almost the entire extracellular region of mouse
FasL (amino acid 101-279) was prepared as described previously
(16), and purified using an anti-mouse FasL mAb affinity column.
Anti-human Fas IgM mAb (CH11) was purchased from MBL
(Nagoya, Japan). To investigate the susceptibility of the cells to sol-
uble FasL or anti-Fas mAb, 2 
 
3
 
 10
 
5
 
 fresh PBL or 6 
 
3
 
 10
 
5
 
 ConA
blasts were cultured with various concentrations of WX1, AL-1,
and CH11 in 200 
 
m
 
l of culture medium in a flat-bottomed 96-
well culture plate for 14 h at 37
 
8
 
C in a 5% CO
 
2
 
, humidified at-
mosphere. The same number of fresh PBL were cocultured with
1A12 cells at various effector/target ratios for 12 h. In some ex-
periments, 1A12 cells were preincubated with 10 
 
m
 
M BB2116 ma-
trix metalloprotease inhibitor (kindly provided by Dr. A.H. Drum-
mond, British Biotech Pharmaceuticals, Oxford, UK) for 4 h, and
it was continuously included in the following assay to obstruct the
cleavage of membrane FasL.
 
Evaluation of Fas Expression and Cell Death by Flow Cytometry.
 
After incubations to induce apoptosis, aliquots of the cells were
stained with optimal doses of FITC-conjugated anti-Fas mAb
(UB-2, MBL), PE-conjugated mAbs against either CD3, CD4, or
CD8 (Becton Dickinson, San Jose, CA), and 2 
 
m
 
g/ml of propid-
ium iodide (PI) in 50 
 
m
 
l of staining solution for 30 min on ice,
and then washed 3 times with staining solution. These cells were
immediately analyzed in a FACScan
 
Ò
 
 (Becton Dickinson) equipped
with a 488-nm argon laser, and the data were analyzed using
CELLQuest software. Percent specific cell killing was calculated
as follows: % specific cell killing 
 
5
 
 (% PI
 
1
 
 cells 
 
2
 
 % spontaneous
PI
 
1
 
 cells in medium only) / (100 
 
2
 
 % spontaneous PI
 
1
 
 cells in
medium only).
Figure 1. Susceptibility of fresh PBT and ConA blasts to anti-Fas mAb
(CH11), soluble human FasL (AL-1), and recombinant soluble mouse
FasL (WX1). (a–c), Fresh PBL or ConA blasts were cultured in the pres-
ence of the indicated concentrations of CH11 (a), AL-1 (b), and WX1 (c)
for 14 h. Cells were then stained with FITC-anti-Fas mAb, PE-conju-
gated mAb against either CD4 or CD8, and PI. Percent specific cell kill-
ing of CD41 and CD81 cells was determined as described in Materials
and Methods. (d–g) Fresh PBL (d and e) and ConA blasts (f and g) cultured
with (solid line) or without (dotted line) 4,000 units/ml of WX1 for 14 h
were stained as described above, and 5 3 104 total cells (including both viable
and dead cells) were analyzed in a FACScanÒ. Staining profiles for FITC-
anti-Fas mAb of viable (PI2) CD41 (d and f) or CD81 cells (e and g) are
shown. 
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Results
 
WX1, but Not Soluble Human FasL or Anti-Fas mAb Kills
Freshly Isolated PBL.
 
About 50% of CD4
 
1
 
 and CD8
 
1
 
 T
cells in freshly isolated PBL from a healthy adult volunteer
and virtually all ConA blasts generated from the PBL ex-
pressed readily detectable levels of Fas (data not shown).
Consistent with previous reports, agonistic anti-Fas mAb
(CH11) efficiently killed ConA blasts, whereas fresh PBT
were resistant to the mAb (Fig. 1 
 
a
 
). We previously estab-
lished a transfectant that expresses a human FasL lacking most
of its cytoplasmic region. This cell line (1A12) secretes sol-
uble FasL by a proteolytic mechanism (23). The soluble
FasL was purified using an affinity column with anti-human
FasL mAb. This purified soluble human FasL (named AL-1)
showed similar target specificity to CH11 (Fig. 1 
 
b
 
). In
contrast, WX1, the biologically active, recombinant soluble
mouse FasL, killed both ConA blasts and fresh PBT (Fig. 1,
 
c–g
 
). Since WX1 specifically killed Fas
 
1
 
 cells in PBT, which
represent 
 
z
 
50% of the total PBT (Fig. 1, 
 
d
 
 and 
 
e
 
), the
dose-response curves of WX1-induced death in ConA blasts
 
and fresh Fas
 
1
 
 PBT are comparable. There was no differ-
ence between CD4 and CD8 T cells in terms of suscepti-
bility to various Fas agonists.
 
Membrane FasL Kills Freshly Isolated PBL, and Soluble FasL
Inhibits This Activity.
 
The cytotoxicity of membrane FasL
to fresh PBT was investigated using a transfectant (1A12)
expressing human FasL and its parental cell line (WR19L).
The metalloprotease inhibitor BB2116 prevents proteolytic
secretion of FasL from 1A12 cells (23). As shown in Fig. 2 
 
a
 
,
1A12 killed fresh PBT in a dose-dependent manner, and
BB2116 dramatically enhanced the cytotoxicity of 1A12.
WR19L showed no cytotoxicity even in the presence of
BB2116. BB2116 did not enhance the cytotoxicity of WX1
(data not shown), excluding the possibility that the weak
toxicity of BB2116 rather than its protease inhibitor activ-
ity caused the enhancement of 1A12-mediated killing. Fas
 
1
 
PBT were specifically killed by 1A12 (Fig. 2, 
 
b–d
 
). We then
tested whether soluble FasL inhibits the cytotoxicity of 1A12
against PBT. As shown in Fig. 2 
 
e
 
, exogenously added sol-
uble FasL inhibited the cytotoxicity of 1A12 in the pres-
ence of BB2116 in a dose-dependent manner. Similarly, anti-
Fas mAb inhibited the killing of PBT by 1A12 (Fig. 2 
 
f
 
).
These results indicate that membrane FasL is capable of
killing fresh Fas
 
1
 
 PBT, whereas soluble FasL and anti-Fas
mAb behave as Fas-antagonists for these cells under the con-
ditions used.
 
IFN-
 
g
 
 or a Combination of IL-2 and Immobilized Anti-CD28
mAb Induces Fas Expression and Susceptibility to 1A12 Cells
and WX1, but Not to AL-1 or CH11 in PBL.
 
Essentially all
cord blood T cells (CBT) are CD45RO
 
2
 
 naive T cells and
do not express Fas at detectable levels. Accordingly, they
are not killed by any form of FasL or anti-Fas mAb (data
not shown). Previously, it was reported that CBT cultured
with phytohemagglutinin for 5 d express Fas (20). Here,
we found that IFN-
 
g
 
 induces Fas expression on both
CD4
 
1
 
 and CD8
 
1
 
 CBT within 20 h (Fig. 3, 
 
a
 
 and 
 
e
 
). IL-2
alone induced FasL weakly, while other stimuli including
IL-1, IL-4, IL-6, TNF-
 
a
 
, and immobilized anti-CD28 mAb
did not, when added separately (Fig. 3, 
 
b
 
,
 
 c
 
,
 
 f
 
,
 
 
 
and
 
 g
 
, and
data not shown). However, a combination of IL-2 and
anti-CD28 mAb showed Fas-inducing activity comparable
to IFN-
 
g
 
 (Fig. 3, 
 
d
 
 and 
 
h
 
). The levels of Fas expression in-
duced by IFN-
 
g
 
 plus anti-CD28 mAb were not much dif-
ferent from those induced by IFN-
 
g
 
 alone (data not
shown).
Finally, we tested the susceptibility of Fas-induced CBT
to various forms of FasL and anti-FasL mAb. As shown in
Fig. 3, 
 
i 
 
and
 
 j
 
, CBT treated with IFN-
 
g
 
 or a combination of
IL-2 and anti-CD28 mAb were killed by 1A12 cells in the
presence of BB2116 and WX1, whereas the same cells
were resistant to AL-1 and CH11.
 
Discussion
 
We have shown that the membrane form of FasL is ca-
pable of killing Fas
 
1
 
 PBT. The Fas
 
1
 
 fraction of PBT corre-
Figure 2. Membrane FasL kills fresh PBT and soluble FasL inhibits the
killing. (a) Fresh PBL were cultured with the transfectant expressing hu-
man FasL (1A12) or its parental cell line (WR19L) at the indicated effec-
tor/target (E/T) ratios for 12 h in the presence or absence of 10 mM
BB2116. Cells were then stained with FITC anti-Fas, PE-anti-CD3 mAb
and PI, and analyzed in a FACScanÒ. (b–d) FITC anti-Fas mAb staining
profiles for PI2CD31 cells after culturing with WR19L in the absence of
BB2116 (b), or with 1A12 in the absence (c) or presence (d) of BB2116 at
an E/T ratio of 1.0 are shown. Dotted profiles indicate negative controls
stained with FITC-labeled mouse IgG1. (e and f). Fresh PBL were cul-
tured with 1A12 plus 10 mM BB2116 or with WR19L cells at the E/T
ratio of 1.0 in the presence of the indicated concentrations of purified
AL-1 (e) or CH11 (f) for 12 h.2048 Differential Cytotoxic Activity of Membrane and Soluble Fas Ligand
sponds to CD45RO1 memory T cells (20). In contrast, na-
ive T cells in adult or cord blood do not express Fas, hence
they are not killed by any types of FasL or anti-Fas mAb.
However, IFN-g and a combination of IL-2 and anti-CD28
mAb rapidly induce Fas expression in naive T cells from cord
blood, and as a result, these cells become sensitive to mem-
brane FasL. We have previously reported that freshly iso-
lated mouse T cells from peripheral lymphoid organs, which
are resistant to anti-mouse Fas mAb, are susceptible to WX1
(16). Collectively, these results demonstrate that the Fas ex-
pressed on the peripheral T cells of humans and mice is
functional. The cytotoxicity of membrane FasL against pe-
ripheral T cells is not specific to transfectants expressing
high levels of FasL, because activated T cells from B10-Thy1a
(Thy1.1) mice induced cell death in naive T cells from B10
(Thy1.2) mice in a FasL-dependent manner (data not shown).
Why should fresh PBT, which are potentially useful cells,
be killed by membrane FasL? T cells are activated through
TCR in an Ag-specific manner. However, once T cells are
activated, they produce a variety of cytokines and cell sur-
face costimulative molecules that can activate bystander T
cells in an Ag-nonspecific manner. Therefore, when some
naive or memory T cells with inappropriate Ag-specificity
accidentally encounter activated T cells at an inflammatory
site, they should be killed, probably through the FasL ex-
pressed by activated T cells; otherwise, they would be acti-
vated Ag-nonspecifically. We previously demonstrated that
TCR engagement induces FasL-resistance in mouse splenic
T cells. Therefore, naive or memory T cells with appropri-
ate TCR, which are thereby acquiring antigenic signals,
would not be killed by activated T cells (16).
Soluble human FasL is biologically active in that it has
potent cytotoxicity against some Fas-expressing cell lines (14).
In contrast, its mouse counterpart is inactive. Since Fas is
constitutively expressed in various tissues, if soluble FasL is
fully functional, it may be detrimental to humans. Here, we
found that soluble human FasL possesses a selective killing
activity. Potentially useful PBT are not killed by AL-1. In
contrast, ConA blasts are killed by AL-1. The latter cells may
represent useless or even dangerous senescent activated T
cells. Human recombinant soluble FasL produced in yeast,
which has a target selectivity similar to naturally processed
soluble FasL (data not shown), induces lethal hepatic failure,
but only when a high dose (500 mg/mouse) of the FasL is
intravenously injected in mice (24). In contrast, the injec-
tion of a small number of CTL can induce lethal hepatitis
in mice (25), and the lethal activity is mediated by FasL (5).
These results suggest that the cytotoxicity of soluble FasL
against hepatocytes is also limited, compared with that of
membrane FasL. This notion has been confirmed by an in
vitro cytotoxicity assay against primary culture hepatocytes
(Tanaka, M., and S. Nagata, manuscript in preparation). It
has been shown that membrane TNF-a is far more effi-
cient than soluble TNF-a in activating type II TNF recep-
tors (26). These results indicate that the membrane forms of
FasL and TNFa are the primary activators of their receptors.
We discovered that soluble human FasL competitively in-
hibits the killing of PBT by membrane FasL. Collectively,
these results indicate that the cleaving of membrane ligands
is a mechanism that partly downregulates their activities.
Why do membrane and soluble FasL have different sets
of target cells? In relation to this phenomenon, various Fas
agonists including soluble and membrane FasL, and anti-Fas
mAbs, can be separated into two groups based on their kill-
ing activity against fresh PBT and ConA blasts. Membrane
FasL and WX1 kill both fresh PBT and ConA blasts, whereas
“agonistic” anti-Fas mAbs and AL-1 kill ConA-activated T
cells but not fresh PBT. Furthermore, the latter group in-
hibits the killing activity of the first group, indicating that
they can bind to Fas on fresh PBT. Since both AL-1 and
WX1 are soluble proteins, solubility is not the reason for
the different activity of the two groups. The fact that puri-
Figure 3. Function of Fas on CBT induced by IFN-g or a combina-
tion of IL-2 and immobilized anti-CD28 mAb. (a–h) Cord blood lym-
phocytes were cultured for 20 h with medium only (dotted line in each
panel), IFN–g (10 ng/ml, a and e), IL-2 (10 ng/ml, b and f), immobilized
anti-CD28 mAb (coated on plate at 10 mg/ml, c and g), or IL-2 plus im-
mobilized anti-CD28 mAb (d and h), respectively. Cells were then stained
with FITC–anti-Fas mAb, PE-conjugated mAb against either CD4 or
CD8, and PI. FITC–anti-Fas mAb staining profiles of viable (PI2) CD41
(a–d) or CD81 cells (e–h) are shown. (i and j) CBT treated with IFN-g or
with IL-2 plus anti-CD28 mAb as described above were cultured with
CH11, WX1, AL-1, or 1A12.2049 Suda et al. Brief Definitive Report
fied WX1 can kill fresh PBT makes it unlikely that an un-
identified molecule coexpressed with membrane FasL on
1A12 cells is required as a costimulative molecule to facili-
tate the FasL-mediated death of fresh PBT. Analytical gel
filtration indicates that AL-1 exists as a trimer (Tanaka, M.,
and S. Nagata, unpublished observation) whereas WX1 mostly
exists as an oligomer larger than a decamer (16). Therefore,
it is possible that the trimerization of Fas is sufficient for it
to kill ConA blasts, whereas the formation of larger com-
plexes of Fas is required for it to kill fresh PBT. However,
this possibility seems unlikely because the anti-human Fas
mAb, CH11, which belongs to the second group, is a de-
cavalent IgM Ab. Furthermore, the super-cross-linking of
Fas on PBT by sequential treatments with CH11 and anti-
mouse IgM antibodies induces only minimal death in CD41
cells, and it has no effect on CD81 cells (data not shown).
The affinities or avidities of various agonists for Fas may de-
termine their spectrum of target cells. Recently, Fadeel et al.
(27) reported that various anti-Fas mAbs that recognize the
same epitope exhibit different effects on Fas-mediated apo-
ptosis, and that those mAbs with a moderate affinity killed
Fas-expressing cells, while high-affinity Abs were antago-
nistic and low-affinity Abs showed no biological effect. How-
ever, the reason why AL-1 inhibits the cytotoxicity of mem-
brane FasL is probably not because AL-1 has a very high
affinity, since rather large doses of AL-1 were required to
inhibit cytotoxicity of membrane FasL. Alternatively, mem-
brane FasL and WX1 but not anti-Fas mAbs or AL-1 may in-
teract with, in addition to Fas, another molecule expressed
in fresh PBT, and this interaction may be necessary to kill
fresh PBT. Since WX1, which is a soluble protein, some-
how mimics membrane FasL rather than soluble FasL, a
careful comparison of WX1 and AL-1 may elucidate this
possibility. WX1 is also a useful tool for investigating the
Fas sensitivity of a group of cells that are only killed by mem-
brane FasL or WX1.
Since agonistic anti-Fas/Apo-1 mAbs show strong cyto-
toxicity against a variety of tumors (28, 29) or abnormally
proliferating synovial cells in rheumatoid arthritis (30), a pos-
sible therapeutic value of these mAbs for these diseases has
been discussed. The main concern has been the toxicity of
these molecules against normal cells. Our finding that some
soluble FasL and an anti-Fas mAb show selective killing ac-
tivity opens up the possibility that some tumor cells or ab-
normally activated cells are more sensitive than normal cells
to these molecules. If this is the case, these molecules at a
sublethal dose may be therapeutic for tumor or rheumatoid
arthritis patients.
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